Core Viewpoint - The article highlights that Seer Medical's strategic subsidiary, Huajiyuan Bio, has initiated a Phase I clinical trial for an innovative drug, HJY-ATRQβ-001 injection, which is a therapeutic vaccine for hypertension targeting the angiotensin II receptor type I. This marks a significant step as it has received ethical approval from the Ethics Committee of Huazhong University of Science and Technology Tongji Medical College Affiliated Union Hospital [1]. Group 1 - Seer Medical's strategic investment in Huajiyuan Bio has led to the development of HJY-ATRQβ-001, an innovative therapeutic vaccine for hypertension [1]. - The Phase I clinical trial is being conducted in collaboration with Standeam (Beijing) Pharmaceutical as the CRO [1]. - The ethical approval from the relevant medical ethics committee signifies a crucial milestone in the drug's journey towards human clinical trials [1].

Group 1 - The core viewpoint of the news is that Sely Medical has seen a stock price increase of 5.89%, reaching 26.24 CNY per share, with a total market capitalization of 5.515 billion CNY [1] - Sely Medical, established on February 23, 2004, and listed on October 31, 2016, specializes in medical testing services, in vitro diagnostic product agency, and the research, production, and sales of its own in vitro diagnostic products [1] - The revenue composition of Sely Medical includes 39.91% from IVD business, 38.01% from SPD business, and 22.08% from pure sales [1] Group 2 - From the perspective of the top ten circulating shareholders, a fund under GF Fund ranks among the top shareholders of Sely Medical, with GF Healthcare Stock A (004851) newly entering the top ten in Q3, holding 1.2236 million shares, which is 0.58% of the circulating shares [2] - The estimated floating profit for GF Healthcare Stock A today is approximately 1.7864 million CNY [2] - GF Healthcare Stock A was established on August 10, 2017, with a latest scale of 5.185 billion CNY, and has achieved a year-to-date return of 19.74%, ranking 2756 out of 4216 in its category [2]

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、可转换公司债券发行上市概况 （一）可转换公司债券发行情况 | 证券代码：603716 | 证券简称：塞力医疗 | 公告编号：2025-094 | | --- | --- | --- | | 债券代码：113601 | 债券简称：塞力转债 | | 塞力斯医疗科技集团股份有限公司 关于"塞力转债"预计满足赎回条件的提示性公告 经中国证券监督管理委员会（证监许可【2020】1033号）核准，公司于2020 年8月21日公开发行了543.31万张可转换公司债券，每张面值100元，发行总额 54,331万元，期限6年。本次发行的可转换公司债券的票面利率为：第一年0.50%， 第二年0.80%，第三年1.00%，第四年1.50%，第五年2.50%，第六年3.00%。 （二）可转换公司债券上市情况 经上海证券交易所自律监管决定书【2020】306号文同意，公司发行总额为 54,331万元的可转换公司债券于2020年9月15日起在上海证券交易所挂牌交易， 债券简称"塞力转债"，债券代码"11 ...

证券代码：603716 证券简称：塞力医疗 公告编号：2025-095 债券代码：113601 债券简称：塞力转债 塞力斯医疗科技集团股份有限公司 关于召开2025年第三季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 会议召开时间：2025 年 11 月 14 日（星期五）10:00-11:00 会议召开地点：价值在线（www.ir-online.cn） 会议召开方式：网络文字互动方式 会 议 问 题 征 集 ： 投 资 者 可 于 2025 年 11 月 14 日 前 访 问 网 址 https://eseb.cn/1sNcORnvdqE 或使用微信扫描下方小程序码进行会前提 问，公司将通过本次业绩说明会，在信息披露允许范围内就投资者普遍 关注的问题进行回答。 公 司 定 于 2025 年 11 月 14 日 （ 星 期 五 ） 10:00-11:00 在 " 价 值 在 线 " （www.ir-online.cn）举办塞力斯医疗科技集团股份有限公司 2025 年第三季度 业绩说明会，与 ...

Market Overview - The pharmaceutical commercial sector declined by 0.5% on November 4, with Baiyang Pharmaceutical leading the drop [1] - The Shanghai Composite Index closed at 3960.19, down 0.41%, while the Shenzhen Component Index closed at 13175.22, down 1.71% [1] Stock Performance - Notable gainers included: - HeFu China (603122) with a closing price of 11.85, up 10.03% [1] - Renmin Tongtai (600829) at 9.71, up 8.01% [1] - Jianfa Zhixin (301584) at 35.42, up 5.20% [1] - Baiyang Pharmaceutical (301015) saw a significant decline, closing at 25.62, down 6.09% [2] - Other notable decliners included: - Yifeng Pharmacy (603939) at 23.76, down 3.22% [2] - Saili Medical (603716) at 24.78, down 3.17% [2] Capital Flow - The pharmaceutical commercial sector experienced a net inflow of 32.34 million yuan from institutional investors, while retail investors saw a net outflow of 41.10 million yuan [2] - The capital flow for key stocks showed: - Renmin Tongtai had a net inflow of 63.04 million yuan from institutional investors [3] - Yifeng Pharmacy experienced a net outflow of 32.44 million yuan from retail investors [3]

Core Insights - The pharmaceutical commercial sector experienced a rise of 0.69% on November 3, with HeFu China leading the gains [1] - The Shanghai Composite Index closed at 3976.52, up 0.55%, while the Shenzhen Component Index closed at 13404.06, up 0.19% [1] Stock Performance Summary - HeFu China (603122) closed at 10.77, with a significant increase of 10.01% and a trading volume of 252,300 shares, amounting to a transaction value of 271 million [1] - Jianfa Zhixin (301584) saw a rise of 3.98%, closing at 33.67 with a trading volume of 143,300 shares [1] - Renmin Tongtai (600829) increased by 3.93%, closing at 8.99 with a trading volume of 337,500 shares [1] - Other notable performers include Jia Shitang (002462) with a 2.43% increase and Sai Li Medical (603716) with a 2.36% increase [1] Capital Flow Analysis - The pharmaceutical commercial sector experienced a net outflow of 78.21 million from institutional investors, while retail investors saw a net inflow of 94.46 million [2] - The top stocks by net inflow from retail investors include Renmin Tongtai (600829) with 17.00 million and Baiyang Pharmaceutical (301015) with 16.33 million [3] - Conversely, institutional investors showed a significant net inflow in Guoyao Yizhi (000028) with 15.04 million, indicating strong institutional interest [3]

Core Insights - The stock price of Sely Medical (603716) increased by 2.92% to 25.0 CNY as of October 31, 2025, with a market capitalization of 5.254 billion CNY [1] Shareholder Changes - As of September 30, 2025, the number of shareholders reached 79,300, an increase of 33,600 or 73.49% compared to June 30, 2025 [3][6] - The average number of shares held per shareholder decreased from 4,180 to 2,651 shares, with an average holding value of 65,900 CNY [3] Performance Disclosure - For the first three quarters of 2025, the main revenue was 857 million CNY, a year-on-year decrease of 39.64% [4][6] - The net profit attributable to shareholders was -87.2441 million CNY, down 55.72% year-on-year [4][6] - The net profit excluding non-recurring items was -103 million CNY, a significant decline of 292.71% [4] - In Q3 2025, the single-quarter main revenue was 274 million CNY, a year-on-year decrease of 38.41% [4] - The single-quarter net profit attributable to shareholders was -31.1249 million CNY, an increase of 39.27% year-on-year [4] - The single-quarter net profit excluding non-recurring items was -31.9451 million CNY, down 58.6% year-on-year [4] - The company's debt ratio stood at 49.61%, with investment income of 7.3433 million CNY and financial expenses of 34.9823 million CNY, while the gross profit margin was 21.73% [4] Company Announcements - On October 29, 2025, the fifth board of directors held its 22nd meeting, where both the Q3 report and the asset impairment provision were approved unanimously [5][6]

Core Insights - The pharmaceutical commercial sector saw a rise of 0.42% on October 31, with HeFu China leading the gains [1] - The Shanghai Composite Index closed at 3954.79, down 0.81%, while the Shenzhen Component Index closed at 13378.21, down 1.14% [1] Stock Performance - HeFu China (603122) closed at 9.79, up 10.00% with a trading volume of 495,400 shares and a transaction value of 479 million [1] - RunDa Medical (603108) closed at 16.87, up 6.50% with a trading volume of 479,200 shares and a transaction value of 792 million [1] - SaiLi Medical (603716) closed at 25.00, up 4.82% with a trading volume of 267,700 shares and a transaction value of 664 million [1] - Other notable performers include First Pharmaceutical (600833) up 4.79% and GuoFa Co. (600538) up 4.36% [1] Capital Flow - The pharmaceutical commercial sector experienced a net inflow of 10.53 million from institutional investors, while retail investors saw a net inflow of 61.38 million [2] - However, speculative funds recorded a net outflow of 71.91 million [2] Individual Stock Capital Flow - RunDa Medical (603108) had a net inflow of 11.1 million from institutional investors, but a net outflow of 66.63 million from speculative funds [3] - SaiLi Medical (603716) saw a net inflow of 32.35 million from institutional investors, with a net outflow of 27.53 million from speculative funds [3] - GuoFa Co. (600511) had a net inflow of 18.53 million from institutional investors, while retail investors experienced a net outflow of 16.86 million [3]

Group 1 - The core point of the news is that Selys Medical experienced a stock price increase of 5.24%, reaching 25.10 CNY per share, with a trading volume of 400 million CNY and a turnover rate of 7.74%, resulting in a total market capitalization of 5.275 billion CNY [1] - Selys Medical Technology Group Co., Ltd. is located in Wuhan, Hubei Province, established on February 23, 2004, and listed on October 31, 2016. The company's main business includes centralized marketing and service for medical testing, agency for in vitro diagnostic products, and research, production, and sales of self-developed in vitro diagnostic products [1] - The revenue composition of Selys Medical is as follows: IVD business accounts for 39.91%, SPD business for 38.01%, and pure sales for 22.08% [1] Group 2 - From the perspective of fund holdings, one fund under Caitong Securities Asset Management has a significant position in Selys Medical. The Caitong Asset Management Healthcare Mixed A Fund (018484) held 200,000 shares in the third quarter, representing 5.72% of the fund's net value, ranking as the tenth largest holding [2] - The Caitong Asset Management Healthcare Mixed A Fund (018484) was established on August 3, 2023, with a latest scale of 64.306 million CNY. Year-to-date returns are 26.17%, ranking 3675 out of 8154 in its category; the one-year return is 25.68%, ranking 3563 out of 8046; and since inception, the return is 11.84% [2]

Core Viewpoint - Seer Medical is a leading enterprise in the domestic medical testing centralized service sector, established in 2004 and listed on the Shanghai Stock Exchange in 2016, with a comprehensive service capability across the entire industry chain [1] Financial Performance - For Q3 2025, Seer Medical reported revenue of 857 million yuan, ranking 21st out of 24 in the industry, significantly lower than the top competitor Shanghai Pharmaceuticals at 215.07 billion yuan and second-place Jiuzhoutong at 119.33 billion yuan, as well as below the industry average of 29.22 billion yuan and median of 14.66 billion yuan [2] - The main business composition includes IVD business at 233 million yuan (39.91%), SPD business at 222 million yuan (38.01%), and pure sales at 129 million yuan (22.08%) [2] - The net profit for the same period was -79.15 million yuan, ranking 23rd out of 24, with a significant gap compared to Shanghai Pharmaceuticals' 5.986 billion yuan and Jiuzhoutong's 2.077 billion yuan, and below the industry average of 611 million yuan and median of 205 million yuan [2] Financial Ratios - As of Q3 2025, Seer Medical's debt-to-asset ratio was 49.61%, down from 63.47% year-on-year and below the industry average of 59.74%, indicating relatively good debt repayment capability [3] - The gross profit margin was 21.73%, up from 19.89% year-on-year and higher than the industry average of 13.11%, reflecting a certain advantage in profitability [3] Executive Compensation - The chairman of Seer Medical, Wen Wei, has a salary of 900,000 yuan for 2024, unchanged from 2023 [4] Shareholder Information - As of September 30, 2025, the number of A-share shareholders increased by 73.49% to 79,300, with an average holding of 2,650.98 shares, down by 36.58% [5] - Among the top ten circulating shareholders, notable changes include the sixth-largest shareholder, Caitong Advantage Industry Rotation Mixed A, increasing holdings by 584,800 shares, and new entries from Guangfa Healthcare Stock A and Caitong Science and Technology Theme Flexible Allocation Mixed [5]